(Malignant Melanoma) Cobimetinib Plus Vemurafenib: coBRIM Phase 3 Trial Results
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- August 5, 2016
- 1 min read
On August 3, 2016, The Lancet Oncology published results demonstrating that the combination of cobimetinib and vemurafenib is effective as first-line treatment for BRAF V600 mutation-positive malignant melanoma.
Vemurafenib is a BRAF inhibitor used in malignant melanoma treatment. The coBRIM trial evaluated vemurafenib combined with cobimetinib (brand name Cotellic, a MAPK MEK inhibitor), confirming a median PFS of 12.3 months. With vemurafenib alone, median PFS was 7.2 months (p<0.0001).
At data analysis (August 28, 2015), 52% of patients had died. Median OS: cobimetinib combination 22.3 months vs. vemurafenib alone 17.4 months (p<0.005).
coBRIM Trial Design (NCT01689519):
The coBRIM trial began in January 2013 across 193 sites in the United States, Europe, Russia, and Israel. It enrolled 495 patients with BRAF V600 mutation-positive unresectable Stage 3c or Stage 4 malignant melanoma. Patients were randomized 1:1 to cobimetinib or placebo, both administered with vemurafenib. Treatment cycle was 28 days: cobimetinib 60 mg once daily for Days 1–21, then 7 days off; vemurafenib 960 mg for all 28 days. Primary endpoints were PFS and OS duration.
Conclusion: The coBRIM trial demonstrated that combination cobimetinib plus vemurafenib is effective for patients with BRAF V600 mutation-positive malignant melanoma.
Source: A Phase III Study Comparing Vemurafenib vs Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With Metastatic Melanoma (coBRIM)
Malignant Melanoma | BRAF V600 | MEK Inhibitor | Targeted Therapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4